Bioventus Selects Bazis NN as Distributor of DUROLANE® in Russia
15.6.2020 16:00:00 EEST | Business Wire | Press release
Bioventus, a global leader in orthobiologic solutions, has selected Bazis NN as its authorized distributor for DUROLANE, its single-injection joint-fluid osteoarthritis (OA) treatment. OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200615005023/en/
DUROLANE is a single-injection, hyaluronic acid product used for joint lubrication in the treatment of pain associated with osteoarthritis in the knee, hip and small joints. (Photo: Business Wire)
According to official statistics, patients with OA make up one quarter of all patients with musculoskeletal system diseases and OA is detected in 4% of the entire adult population.1 Hyaluronic acid (HA)-based products like DUROLANE and DUROLANE SJ help manage pain in the knees, hips, wrists, elbows, ankles, finger and toe joints of patients with OA.
“We believe the OA market in Russia is underserved and the patients there will benefit greatly from DUROLANE,” said John Nosenzo, Chief Commercial Officer, Bioventus. “Bazis has a terrific track record in marketing and selling orthopaedic solutions in Russia and we are pleased they are helping Bioventus reach more patients and physicians with our proven pain reliever for osteoarthritis.”
“Bazis has been serving patients and physicians in Russia for more than 16 years,” said Aleksandr Alekseev, Director, Bazis NN. “We are excited to offer DUROLANE for knee and hip and DUROLANE SJ for small joints. Both are safe, single injection options for patients that provide powerful and long-lasting OA pain relief.”
DUROLANE and DUROLANE SJ are produced using a natural, safe and proven process called NASHA ® . This process yields stabilized (HA) which is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. It has been proven to provide greater reduction in OA knee pain versus Synvisc-One®2* and longer lasting pain relief versus a steroid injection3. DUROLANE is also safe for repeated courses of therapy. Repeated use of DUROLANE does not increase the incidence of adverse events.4
About Bioventus
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, www.bioventusglobal.com and follow the company on LinkedIn and Twitter.
Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.
Summary of Indication for Use: DUROLANE (3ml): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. DUROLANE SJ (1ml): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes. DUROLANE SJ is also indicated for pain following joint arthroscopy in the presence of osteoarthritis within three months of the procedure. There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant and breastfeeding women, and in children. Risks can include transient pain, swelling and/or stiffness at the injection site. Indications presented are those approved in Russia; indications and product offerings vary by country. Consult with your local Bioventus representative for approved use within your region of interest. Full prescribing information can be found in product labeling, at www.durolane.com.(1mL / 3mL).
References: 1. Kabalyk M.A. Prevalence of Osteoarthritis in Russia: Regional Aspects of Trends in Statistical Parameters During 2011–2016 Rheumatology Science and Practice. 2018;56(4):416-422. (In Russ.) doi:10.14412/1995-4484-2018-416-422. 2. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis. 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 3. Leighton R, Åkermark C, Therrien R, et. al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014; 22(1):17-25. 4. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2018.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005023/en/
Contact information
Thomas Hill
919-474-6715
thomas.hill@bioventusglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Confirmed as the World’s Leading Food Company for Reputation - Ranking 9 th Overall Globally8.4.2026 15:42:00 EEST | Press release
For the third year in a row, Barilla is confirmed as the world’s leading company in the food sector for reputation in the Global RepTrak® 100 ranking conducted by RepTrak, which since 1999 has annually analyzed the companies with the strongest reputations worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407912080/en/ In the 2026 ranking, the Group reaches 9th place overall, moving up 16 spots compared to 2025 (ranked at 25th) and entering the global Top 10, confirming the company’s steady reputation‑building journey developed over the years. This result reflects Barilla’s ability to combine product quality, industrial vision and social responsibility – factors that are increasingly central to the assessment of corporate reputation. The study evaluates key elements including performance, innovation, governance, sustainability and the ability to generate long‑term trust. “In today’s turbulent macroeconomic environm
Adtran launches Ensemble Cloudlet multi‑node to simplify high‑availability edge AI deployments8.4.2026 15:30:00 EEST | Press release
Adtran today launched its Ensemble Cloudlet multi‑node solution, a high‑availability edge platform that supports AI inference and agentic AI deployments where low latency, resilience and secure local processing are critical. Removing the complexity and cost barriers that slow modern service and enterprise deployments, the solution creates a single, logical cloud with distributed storage and automated failover, starting with just two nodes. Built on Cloudlet OS and managed through Ensemble EdgeView orchestration, it enables zero-touch deployment and unified lifecycle management, providing a simple, scalable foundation for running networking, IT and emerging AI workloads at the edge. “Deploying high‑availability edge infrastructure for AI has often demanded a lot of cloud wizardry – stitching together storage, networking and failover manually. With Ensemble Cloudlet multi‑node, we’ve made the hard parts easy,” said Christoph Glingener, CTO of Adtran. “The nodes build their own shared sto
ZincFive Announces Nickel-Zinc Retrofit Kit to Modernize Existing UPS Energy Storage Infrastructure8.4.2026 15:05:00 EEST | Press release
ZincFive®, the global leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today announced the NiZn Retrofit Kit, an uninterruptible power supply (UPS) energy storage solution designed to bring the benefits of modern battery chemistry to existing UPS battery systems in mission-critical environments. The NiZn Retrofit Kit will enable data center operators and service providers to replace legacy valve-regulated lead-acid (VRLA) batteries with ZincFive’s long-life, high-performance nickel-zinc technology without requiring cabinet enclosure replacement, system redesign, or operational disruption. As data center power demands continue to increase, operators face growing pressure to improve reliability, reduce lifecycle costs, and meet sustainability targets. At the same time, much of the global UPS energy storage system installed base remains constrained by legacy VRLA batteries, where full storage system replacement introduces significant cost, complexity,
Sagard and Unigestion Announce Closing of Partnership Transaction8.4.2026 15:00:00 EEST | Press release
Sagard, a global multi-strategy alternative asset management firm with over $45 billion USD1 in assets under management and Unigestion Private Equity Holding SA (UNG PE), a leading middle market private equity provider, today announced the successful closing of their combination transaction, originally announced in September. Completion of this transaction marks the formal launch of the partnership and the integration of UNG PE into Sagard’s global middle-market private equity platform, Sagard Private Equity Solutions (SPES). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408374851/en/ “We are thrilled to formally begin our partnership with the Unigestion team,” said Paul Desmarais III, Chairman & CEO of Sagard. “This milestone solidifies our joint commitment to building a global private equity platform positioned for long-term growth alongside our clients and teams.” “The closing of this transaction represents an excitin
New Research Finds AI Is Now Foundational to Modern Marketing8.4.2026 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced its participation in a new marketing research study conducted by Callan Consulting, a Silicon Valley executive marketing consulting firm, joining 18 B2B and B2C technology companies to examine how AI is reshaping modern marketing organizations, marking a clear shift from early experimentation to embedded, enterprise‑wide adoption. According to the State of AI in Technology Marketing 2026 report, based on in‑depth interviews with CMOs and senior marketing leaders at the participating companies, the study finds that AI is becoming rapidly integrated across core marketing teams and workflows—from content development and research to campaign optimization and analytics. As adoption deepens, data quality, accessibility, and governance are emerging as critical priorities. "AI doesn't change what great marketing is supposed to do. It just removes the excuses for not doing it," said Gabie Boko, Chief Marketing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom